Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation

Out of the breast cancer subtypes, triple-negative breast cancer (TNBC) has the poorest prognosis without effective targeted therapies. Metformin, a first-line drug for type 2 diabetes mellitus, was demonstrated to target breast cancer stem cells selectively. However, the efficiency and the mechanis...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cell Discov
Asıl Yazarlar: Shi, Peiguo, Liu, Wenjing, Tala, Wang, Haixia, Li, Fubing, Zhang, Hailin, Wu, Yingying, Kong, Yanjie, Zhou, Zhongmei, Wang, Chunyan, Chen, Wenlin, Liu, Rong, Chen, Ceshi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5396048/
https://ncbi.nlm.nih.gov/pubmed/28480051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/celldisc.2017.10
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller